The Cancer Letter this week published an interview with Anthony Letai, a researcher at Dana-Farber Cancer Institute, under a headline that cuts against the prevailing mood in US biomedical research: "Perceptions aside, money is flowing and the cancer research infrastructure is sturdy."

The syndicated headline itself is the substance available here — the underlying interview text did not accompany the feed item — but the framing alone warrants attention from R&D managers tracking the funding environment.

Letai's core claim, as captured in the headline, is that the perception of a collapsing cancer research enterprise — a narrative that has circulated widely since federal funding uncertainty and policy turbulence dominated coverage of the NIH and NCI budgets — does not match the observable reality of money still moving through the system and infrastructure remaining intact.

For portfolio planners, this is a data point in an ongoing argument rather than a settled finding. Letai is making an assertion about aggregate conditions, not presenting measured figures in the headline itself. The full interview presumably supplies the numbers and evidence behind that assertion — grant award rates, institutional budget positions, or industry pipeline activity — and readers making budget decisions should weigh those specifics against the counter-evidence: hiring freezes, terminated grants, and delayed study sections that other institutions have documented over the same period.

Letai's position carries weight in the field. He leads work on functional precision medicine — the BH3 profiling approach to predicting cancer drug response — and speaks regularly on how translational research should be organized and funded. When a scientist with an active lab and industry-facing platform says the infrastructure is sturdy, the claim is worth interrogating on its own terms: sturdy compared with what baseline, over what time horizon, and at which institutions.

The perception-versus-reality framing also matters for hiring and capital allocation. If perceptions of scarcity drive good candidates out of the field or push startups to hoard cash, a gap between perception and reality becomes self-fulfilling. Letai's intervention, as headlined, is an attempt to correct that loop before it compounds.

The Cancer Letter's full interview is the place to find the evidence behind the headline, including any figures Letai cites on funding flows.